Full-Time

Event Planning Director

Posted on 12/12/2025

Deadline 10/22/27
American Heart Association

American Heart Association

5,001-10,000 employees

Compensation Overview

$62.7k - $83.7k/yr

Honolulu, HI, USA

In Person

Category
Operations & Logistics (1)
Requirements
  • Minimum of three (3) years’ experience with special events management in a highly matrixed and customer centric environment, including experience managing high volume vendor relationships and large format builds
  • Demonstrated ability to organize and manage multiple projects, prioritize tasks, and meet deadlines with proactive communication, thorough planning and execution and allocating/providing resources, additional support or training
  • Highly effective interpersonal and communication skills, ability to consistently maintain a professional, calm and friendly manner in creating positive customer experiences externally and internally
  • Proven problem-solving skills with the ability to identify potential issues that may impact organizational productivity and/or compliance and address proactively and timely
  • Effective project management and event management skills in a dynamic environment with multiple stakeholders
  • Experience in positively managing change including anticipating and championing organizational change, creating contingency plans, proactively considering short-term and long-term impact
  • Experience in negotiating services and managing service level agreements
  • Ability to do local travel; requires access to reliable transportation at all times on an immediate basis
  • Bachelor's degree or equivalent
Responsibilities
  • Plans, manages, and implements assigned events for the American Heart Association. This includes all aspects of event planning: event design, vendor selection and management, contract negotiation, visual innovation, budget oversight, resource optimization, and execution excellence. Continuously evaluates the effectiveness of event plans and implementation processes, identifying opportunities to improve efficiency, collaboration, and the overall attendee experience.
  • Researches, secures, manages, and evaluates vendors to provide necessary services for assigned events, ensuring compliance with purchasing and operating guidelines and staying within budget. Solicits competitive bids for all event needs and proactively seeks cost-saving opportunities.
  • In collaboration with Development and Communications & Marketing, plans visual and interactive event elements and designs printed materials such as invitations, flyers, bidder paddles, presentations, signage, and other collateral, while adhering to the American Heart Association’s branding guidelines. Ensures all materials and signage are produced on schedule and meet event needs.
  • Provides leadership in recruiting, orienting, and training event volunteers. Develops staffing plans and leads volunteer management for assigned events.
  • Demonstrates a comprehensive understanding of sponsor benefits and ensures their delivery throughout the year for assigned events. Develops innovative ways to showcase sponsors and highlight their activations at American Heart Association events.
  • Secures necessary permits for assigned events.Manages customer and campaign information using American Heart Association systems accurately, timely, and completely, in accordance with established guidelines.
  • Proactively communicates and coordinates timelines and efforts with staff and volunteer partners to ensure strong collaboration and alignment with campaign goals.
Desired Qualifications
  • Knowledge of the American Heart Association’s standards and procedures
  • Experience with sales or fundraising strategies
  • Experience managing staff and volunteer
American Heart Association

American Heart Association

View

Company Size

5,001-10,000

Company Stage

Grant

Total Funding

$700K

Headquarters

Dallas, Texas

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Heart Walk, Kids Heart Challenge rank top 5 U.S. fundraisers nationally.
  • Global expansion via CPR guidelines forums across MENA, India, Japan.
  • Corporate partnerships with Alnylam, Charles River accelerate research and awareness.

What critics are saying

  • Corporate sponsor dependence undermines independence; Alnylam partnership promotes proprietary drugs.
  • New dietary guidelines face backlash, eroding credibility with health professionals.
  • $20M Fontan program risks failure to deliver monitoring tools, damaging reputation.

What makes American Heart Association unique

  • Largest nonprofit cardiovascular research funder with 100+ year track record.
  • 35 million global volunteers amplify reach beyond traditional nonprofit scale.
  • Convenes multidisciplinary health systems for care coordination and quality improvement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Employee Assistance Program

Wellness Program

Telemedicine

Tuition Reimbursement

Paid Vacation

Paid Holidays

Hybrid Work Options

Remote Work Options

Company News

Contract Pharma
Apr 10th, 2026
Charles River, American Heart Association partner to advance cardiovascular health awareness.

Charles River, American Heart Association partner to advance cardiovascular health awareness. Charles River to support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. April 10, 2026 Associate Editor Charles River Laboratories International Inc. has partnered with the American Heart Association to support cardiovascular disease awareness, prevention, and community health initiatives. Through this collaboration, Charles River will support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." The joint effort comes at a critical time for public health. According to the American Heart Association's recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in the United States, while stroke is now the fourth-leading cause of death. Together, heart disease and stroke account for more than one in four U.S. deaths, despite recent improvements in overall cardiovascular mortality. While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association's update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health. More Charles River news. Therna Biosciences, a biotechnology company pioneering programmable RNA therapeutics, recently joined forces with Charles River to advance single-patient RNA medicines for individuals with severe, ultra-rare disorders.

HealthTech HotSpot
Apr 9th, 2026
Charles River advances cardiovascular health awareness Through support of the American Heart Association.

Charles River advances cardiovascular health awareness Through support of the American Heart Association. WILMINGTON, Mass.-(BUSINESS WIRE)-$CRL #CDMO-Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with the American Heart Association, the world's leading nonprofit organization focused on heart and brain health, to support cardiovascular disease awareness, prevention, and community health initiatives. "New data from the American Heart Association shows that cardiovascular disease continues to take an enormous toll on families and communities," said Kristen Eisenhauer, Chief Commercial Officer, Charles River. "We are proud to support the prevention, education, and science-driven efforts needed to help sustain progress and improve cardiovascular health worldwide." Through this collaboration, Charles River will support the American Heart Association's Heart of Boston campaign, helping drive efforts to improve health outcomes across Greater Boston and the country. The support reinforces shared commitments to science-driven progress, prevention, and community engagement, and aligns with Charles River's corporate purpose - Together, HealthTech HotSpot LLC Create Healthier Lives - and its Corporate Citizenship strategy focused on advancing human health beyond the laboratory. The joint effort comes at a critical time for public health. According to the American Heart Association's recently released 2026 Heart Disease and Stroke Statistics Update, heart disease remains the leading cause of death in the United States, while stroke is now the fourth-leading cause of death. Together, heart disease and stroke account for more than one in four U.S. deaths, despite recent improvements in overall cardiovascular mortality. While the latest data shows a decline in total cardiovascular deaths following years of increases associated with the COVID-19 pandemic, the American Heart Association's update underscores persistent risk factors across the population, including high rates of high blood pressure, diabetes, and obesity. These findings highlight the continued need for education, research, and public-private partnerships to advance long-term cardiovascular health. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Its dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more, visit www.criver.com. Charles River Investor Contact: Todd Spencer Corporate Vice President, Investor Relations 781.222.6455 [email protected] Charles River Media Contact: Amy Cianciaruso Corporate Senior Vice President, Chief Communications Officer 781.222.6168 [email protected] April 10th, 2026 April 9th, 2026

Business Insider
Apr 7th, 2026
SimpliFed raises $10.8M Series A to expand virtual maternal health platform from lactation to full OB care

SimpliFed, a virtual maternal healthcare platform, has raised $10.8 million in an oversubscribed Series A round led by Morningside and Hesperia Capital. Foreground Capital and existing investors including AHA Social Impact Fund and Elizabeth Street Ventures participated. The company, which provides virtual breastfeeding and baby feeding support, is expanding into virtual OB services to offer prenatal and postpartum care for low-risk patients. SimpliFed connects families with certified lactation consultants and maternal health providers through telehealth visits, integrating with major electronic medical record systems. SimpliFed is on track to serve 5% of all US births in 2026 and is in network with major commercial health plans and Medicaid across several states. The funding will support growth of its Maternal Health Operating System and partnerships with health systems and OBGYN clinics.

American Heart Association
Mar 30th, 2026
New $20M effort aims to address critical gaps in care for people with single ventricle heart disease.

New $20M effort aims to address critical gaps in care for people with single ventricle heart disease. The American Heart Association and Additional Ventures develop program focused on improving long-term health for people living with Fontan circulation DALLAS, March 30, 2026 - The lifesaving surgery used to treat children with single ventricle heart disease, the Fontan procedure, can pose serious health complications throughout life. The American Heart Association, devoted to changing the future to a world of healthier lives for all and Additional Ventures, a research foundation working toward a cure for single ventricle heart disease, have committed a combined $20M to advance a coordinated, collaborative approach to improving the ability to predict, prevent and treat health complications in people living with Fontan circulation. Single ventricle heart disease affects about 6 in 10,0000 babies born in the US each year[1]. These children are born with only one working heart pump and must rely on a surgically created circulation (the Fontan circulation) to reroute blood through the body. While lifesaving, this circulation places long-term strain on the body and can lead to progressive damage across multiple organs. Today, clinicians lack reliable ways to monitor Fontan health, making them unable to detect early signs of decline. As a result, many patients appear stable until they suddenly experience severe complications that can be fatal or severely impact quality of life. The program will bring together clinicians, researchers and patients to generate scientific and clinical insights and develop tools to better guide care for people living with Fontan circulation. The program combines the strength of the American Heart Association's research infrastructure, guideline development, data coordination and registry science with Additional Ventures' leadership in single ventricle strategy, deep scientific expertise and unparalleled network across the single ventricle heart disease ecosystem. "People with Fontan circulation often develop complications with other organs in the body including the liver, kidneys and lungs," said Mariell Jessup, M.D., FAHA, chief medical and science officer of the American Heart Association. "The coordination between our two organizations will generate data and insight that can help patients and clinicians better monitor their health and intervene earlier." "While lifesaving, Fontan circulation creates complex, lifelong health challenges for single ventricle heart disease patients that we still do not fully understand," said Kirstie Keller, PhD, chief executive officer of Additional Ventures. "Through this collaboration, we will work with researchers, clinicians and patients to generate the scientific insights and tools needed to predict, detect and manage complications earlier. By building these resources, we hope to enable a more proactive, science-informed approach to lifelong care for Fontan patients. The six-year, multi-phase strategy begins with evaluating current approaches to monitoring Fontan circulation patients; identifying gaps in care, data and infrastructure; and engaging patients, clinicians and scientists in program design and implementation. Ultimately, the goal is to establish the scientific foundation and clinical tools needed to move the field from reactive care to proactive health monitoring of patients with Fontan circulation, creating the infrastructure for a future standard of care. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1. About Additional Ventures Additional Ventures is a research foundation committed to curing single ventricle heart disease through transformative research and strategic investments that revolutionize treatment and care. By combining deep scientific expertise with strategic, flexible funding, Additional Ventures supports bold, collaborative research across the translational pipeline. Since its founding in 2020, Additional Ventures has committed more than $110 million to single ventricle heart disease research. Learn more about our work and progress in our most recent Impact Report, at additionalventures.org, or by following us on LinkedIn. For Media Inquiries: 214-706-1173 For Public Inquiries: 1-800-AHA-USA1 (242-8721)

CBS News
Mar 29th, 2026
New heart health dietary guidelines.

New heart health dietary guidelines. The American Heart Association has released new dietary guidelines on how to stay heart healthy to improve quality of life and save lives. Dr. Celine Gounder breaks down what to know. 4h ago Around the web. 60 minutes.

INACTIVE